Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
43,555,026
-
Share change
-
+2,082,014
-
Total reported value
-
$564,029,588
-
Put/Call ratio
-
187%
-
Price per share
-
$12.97
-
Number of holders
-
110
-
Value change
-
+$26,762,019
-
Number of buys
-
62
-
Number of sells
-
40
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2019
As of 30 Jun 2019 Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 43,555,026 shares of stock of the company.
Largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, ArrowMark Colorado Holdings LLC, BlackRock Inc., FRANKLIN RESOURCES INC, Essex Woodlands Management, Inc., JPMORGAN CHASE & CO, Bank of New York Mellon Corp, VANGUARD GROUP INC, ALLIANCEBERNSTEIN L.P., and Capital World Investors.
This table shows 110 institutional shareholders of the security as of 30 Jun 2019.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.